{"id":"F2023L00157","name":"Statement of Principles concerning vascular neurocognitive disorder (Balance of Probabilities) (No. 10 of 2023)","slug":"statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":441725,"registerId":"F2023L00157-fast-fetch-1775956956153","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning vascular neurocognitive disorder (Balance of Probabilities) (No. 10 of 2023)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 22.10.0\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nVASCULAR NEUROCOGNITIVE DISORDER (Balance of Probabilities)\n\n(No. 10 of 2023)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 27 February 2023\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n|
Professor Terence Campbell AM
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Repeal\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning vascular neurocognitive disorder (Balance of Probabilities) (No. 10 of 2023).\n\n2 Commencement\n\n This instrument commences on 27 March 2023.\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n4 Repeal\n\nThe Statement of Principles concerning vascular dementia No. 79 of 2014 (Federal Register of Legislation No. F2014L01141) made under subsection 196B(3) of the VEA is repealed.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about vascular neurocognitive disorder and death from vascular neurocognitive disorder.\n\nMeaning of vascular neurocognitive disorder\n\n(2) For the purposes of this Statement of Principles, vascular neurocognitive disorder means a chronic vascular disorder of the brain, meeting the following clinical diagnostic criteria (derived from DSM-5-TR):\n\n \n\n1. Evidence of major neurocognitive disorder or mild neurocognitive disorder.\n\n\n \n\nB. The clinical features are consistent with a vascular aetiology, as suggested by either of the following:\n\n(i) onset of the cognitive deficits is temporally related to one or more documented cerebrovascular events; or\n\n(ii) evidence for decline is prominent in complex attention (including processing speed) and frontal-executive function.\n\n \n\nC. There is evidence of the presence of cerebrovascular disease from history, physical examination, and/or neuroimaging considered sufficient to account for the neurocognitive deficits.\n\n \n\nD. Vascular neurocognitive disorder includes:\n\n(i) acquired diffuse white matter disease (Binswanger disease);\n\n(ii) multi-infarct dementia;\n\n(iii) post-stroke dementia;\n\n(iv) strategic infarct dementia; \n\n(v) subcortical ischaemic vascular dementia;\n\n(vi) dementia, major neurocognitive disorder or mild neurocognitive disorder due to vascular disease, including atherosclerosis;\n\n(vii) vascular mild cognitive impairment without dementia. \n\n \n\nE. The cognitive deficits in Criteria A, B, C and D are not primarily due to any of the following:\n\n(i) delirium;\n\n(ii) another mental disorder (for example, major depressive disorder, schizophrenia); or\n\n(iii) inherited diffuse white matter disease, mitochondrial disorders, a neurodegenerative disease (for example, Alzheimer disease, Parkinson's disease, Huntington's chorea), brain tumour, subdural haematoma, the effects of a substance, or systemic disorder (for example, hypothyroidism, vitamin B12 or folic acid deficiency, niacin deficiency, hypercalcaemia, neurosyphilis, human immunodeficiency virus infection).\n\nNote 1: DSM-5-TR, major neurocognitive disorder and mild neurocognitive disorder are defined in the Schedule 1 – Dictionary.\n\nNote 2: Vascular neurocognitive disorder is also known as vascular dementia.\n\n(3) While vascular neurocognitive disorder attracts ICD‑10‑AM code F01, in applying this Statement of Principles the meaning of vascular neurocognitive disorder is that given in subsection (2).\n\n(4) For subsection (3), a reference to an ICD-10-AM code is a reference to the code assigned to a particular kind of injury or disease in The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM), Tenth Edition, effective date of 1 July 2017, copyrighted by the Independent Hospital Pricing Authority, ISBN 978-1-76007-296-4.\n\nDeath from vascular neurocognitive disorder\n\n(5) For the purposes of this Statement of Principles, vascular neurocognitive disorder, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's vascular neurocognitive disorder.\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that vascular neurocognitive disorder and death from vascular neurocognitive disorder can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\nNote: MRCA, relevant service and VEA are defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, vascular neurocognitive disorder or death from vascular neurocognitive disorder is connected with the circumstances of a person's relevant service:\n\n(1) having a cerebrovascular accident or subarachnoid haemorrhage before the clinical onset of vascular neurocognitive disorder;\n\n(2) having a specified disease of the cerebral vessels, in the presence of neuroimaging (magnetic resonance imaging or computed tomography) findings of cerebral white matter lesions, haemorrhage or infarction, before the clinical onset of vascular neurocognitive disorder;\n\nNote 1: specified disease of the cerebral vessels is defined in the Schedule 1 – Dictionary.\n\nNote 2: neuroimaging (magnetic resonance imaging or computed tomography) findings is defined in the Schedule 1 – Dictionary.\n\n(3) having hypertension at least 5 years before the clinical onset of vascular neurocognitive disorder;\n\n(4) having sick sinus syndrome, atrial fibrillation or atrial flutter, at the time of the clinical onset of vascular neurocognitive disorder;\n\n(5) having carotid artery disease, ischaemic heart disease or heart failure before the clinical onset of vascular neurocognitive disorder;\n\n(6) having cardiac surgery within the 12 months before the clinical onset of vascular neurocognitive disorder;\n\n(7) having diabetes mellitus for at least the 5 years before the clinical onset of vascular neurocognitive disorder;\n\n(8) having smoked tobacco products:\n\n(a) in an amount of at least 20 pack-years before the clinical onset of vascular neurocognitive disorder; and\n\n(b) commencing at least 5 years before the clinical onset of vascular neurocognitive disorder; and\n\nif smoking has ceased before the clinical onset of vascular neurocognitive disorder, then that onset occurred within 20 years of cessation;\n\nNote: one pack-year is defined in the Schedule 1 - Dictionary.\n\n(9) an inability to undertake any physical activity greater than 3 METs for at least 5 years within the 20 years before the clinical onset of vascular neurocognitive disorder;\n\nNote: MET is defined in the Schedule 1 - Dictionary.\n\n(10) having depressive disorder at least 5 years before the clinical onset of vascular neurocognitive disorder;\n\n(11) having chronic kidney disease before the clinical onset of vascular neurocognitive disorder;\n\nNote: chronic kidney disease is defined in the Schedule 1 - Dictionary.\n\n(12) inhaling ambient, chronically polluted air as specified for at least 2,000 hours within the 5 years before the clinical onset of vascular neurocognitive disorder;\n\nNote: ambient, chronically polluted air as specified is defined in the Schedule 1 – Dictionary\n\n(13) having moderate to severe traumatic brain injury at least 5 years before the clinical onset of vascular neurocognitive disorder;\n\n(14) having a cerebrovascular accident or subarachnoid haemorrhage before the clinical worsening of vascular neurocognitive disorder;\n\n(15) having a specified disease of the cerebral vessels, in the presence of neuroimaging (magnetic resonance imaging or computed tomography) findings of cerebral white matter lesions, haemorrhage or infarction, before the clinical worsening of vascular neurocognitive disorder;\n\nNote: specified disease of the cerebral vessels is defined in the Schedule 1 – Dictionary\n\nNote 2: neuroimaging (magnetic resonance imaging or computed tomography) findings is defined in the Schedule 1 – Dictionary.\n\n(16) having hypertension at least 5 years before the clinical worsening of vascular neurocognitive disorder;\n\n(17) having sick sinus syndrome, atrial fibrillation or atrial flutter, at the time of the clinical worsening of vascular neurocognitive disorder;\n\n(18) having carotid artery disease, ischaemic heart disease or heart failure before the clinical worsening of vascular neurocognitive disorder;\n\n(19) having cardiac surgery within the 12 months before the clinical worsening of vascular neurocognitive disorder;\n\n(20) having diabetes mellitus for at least the 5 years before the clinical worsening of vascular neurocognitive disorder;\n\n(21) having smoked tobacco products:\n\n(a) in an amount of at least 20 pack-years before the clinical worsening of vascular neurocognitive disorder; and\n\n(b) commencing at least 5 years before the clinical worsening of vascular neurocognitive disorder; and\n\nif smoking has ceased before the clinical worsening of vascular neurocognitive disorder, then that onset occurred within 20 years of cessation;\n\nNote: one pack-year is defined in the Schedule 1 - Dictionary.\n\n(22) an inability to undertake any physical activity greater than 3 METs for at least 5 years within the 20 years before the clinical worsening of vascular neurocognitive disorder;\n\nNote: MET is defined in the Schedule 1 - Dictionary.\n\n(23) having depressive disorder at least 5 years before the clinical worsening of vascular neurocognitive disorder;\n\n(24) having chronic kidney disease before the clinical worsening of vascular neurocognitive disorder;\n\nNote: chronic kidney disease is defined in the Schedule 1 - Dictionary.\n\n(25) inhaling ambient, chronically polluted air as specified for at least 2,000 hours within the 5 years before the clinical worsening of vascular neurocognitive disorder;\n\nNote: ambient, chronically polluted air as specified is defined in the Schedule 1 – Dictionary\n\n(26) having moderate to severe traumatic brain injury at least 5 years before the clinical worsening of vascular neurocognitive disorder;\n\n(27) inability to obtain appropriate clinical management for vascular neurocognitive disorder.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(14) to 9(27) apply only to material contribution to, or aggravation of, vascular neurocognitive disorder where the person's vascular neurocognitive disorder was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n albuminuria means an albumin to creatinine ratio of at least 3 milligrams/millimole.\n\n ambient, chronically polluted air as specified means air with average annual concentrations of particulate matter with an aerodynamic diameter of < 2.5 µm (PM2.5) exceeding 25 µg/m3.\n\n cerebral arteriolosclerosis means thickening of the walls of small arteries or arterioles of the brain, due to cell proliferation or hyaline deposition.\n\n chronic kidney disease means:\n\n(a) having a glomerular filtration rate of less than 60 ml/min/1.73 m2 for at least 3 months;\n\n(b) having albuminuria for at least 3 months;\n\n(c) having kidney damage, as evidenced by renal biopsy, imaging studies, urinary sediment abnormalities or other markers of abnormal renal function; or\n\n(d) having had a kidney transplant.\n\nNote: albuminuria is also defined in the Schedule 1 - Dictionary.\n\n DSM-5-TR means the American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision. Washington, DC, American Psychiatric Association, 2022.\n\n major neurocognitive disorder means:\n\n(a) evidence of significant cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on:\n\n(i) concern of the individual, a knowledgeable informant, or the clinician that there has been a significant decline in cognitive function; and\n\n(ii) a substantial impairment in cognitive performance, documented by standardised neuropsychological testing or another qualified clinical assessment; and\n\n(b) the cognitive deficits interfere with independence in everyday activities (that is, at a minimum, requiring assistance with complex instrumental activities of daily living such as paying bills or managing medications).\n\n \n\n MET means a unit of measurement of the level of physical exertion. 1 MET = 3.5 ml of oxygen/kg of body weight per minute, 1.0 kcal/kg of body weight per hour or resting metabolic rate.\n\n mild neurocognitive disorder means evidence of modest cognitive decline from a previous level of performance in one or more cognitive domains (complex attention, executive function, learning and memory, language, perceptual-motor, or social cognition) based on:\n\n(a) concern of the individual, a knowledgeable informant, or the clinician that there has been a mild decline in cognitive function; and\n\n(b) a modest impairment in cognitive performance, documented by standardised neuropsychological testing or another qualified clinical assessment.\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n neuroimaging (magnetic resonance imaging or computed tomography) findings means an image of an interior of a body obtained by medical techniques, that is usually obtained at a date after the clinical onset of the disease.\n\n one pack-year means the amount of tobacco consumed in smoking 20 cigarettes per day for a period of 1 year, or an equivalent amount of tobacco products.\n\nNote 1: An equivalent amount of tobacco products is 7,300 grams of smoking tobacco by weight, either in cigarettes, pipe tobacco or cigars, or a combination of same. For pipe tobacco, cigars or combinations of multiple tobacco types, 1 gram of tobacco is considered to be equal to one cigarette.\n\nNote 2: Pack-years are calculated by dividing the number of cigarettes smoked per day by 20 and multiplying this number by the number of years the person has smoked. For example, smoking 10 cigarettes per day for 10 years is equal to 5 pack-years, and smoking 40 cigarettes per day for 10 years is equal to 20 pack-years.\n\n relevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified disease of the cerebral vessels means:\n\n(a) antiphospholipid syndrome;\n\n(b) cerebral amyloid angiopathy;\n\n(c) cerebral arteriolosclerosis;\n\n(d) cerebral venous thrombosis;\n\n(e) hippocampal sclerosis of vascular origin (seen in temporal lobe epilepsy, hypoxic/ischaemic brain injury);\n\n(f) inflammatory or immunologically mediated vasculitis;\n\n(g) intravascular lymphomatosis (a type of non-Hodgkin lymphoma); \n\n(h) laminar cortical necrosis; or\n\n(i) Moyamoya disease;\n\nNote: cerebral arteriolosclerosis is also defined in the Schedule - 1 Dictionary.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n vascular neurocognitive disorder—see subsection 7(2).\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"This instrument broadens and updates the earlier 2014 Statement of Principles in several concrete ways. It modernises the diagnostic standard by adopting DSM‑5‑TR terminology (including both major and mild neurocognitive disorder) rather than older language (s7(2), Schedule 1). It expands the range of listed contributing factors (for example, explicit inclusion of ambient PM2.5 exposure, specific measures of physical inactivity, depressive disorder, chronic kidney disease and inability to obtain appropriate clinical management — s9 and Schedule 1). It also creates separate rules for material contribution or aggravation of pre-existing disease (s9(14)–(27) and s10(2)), and treats death from a terminal event contributed to by the disorder as included (s7(5)). Those changes collectively broaden the scope of conditions and exposures that can support a service connection, and update thresholds and diagnostic references compared with the instrument it repeals (s4)."},"complexity_factors":["Multiple cross-references to other instruments and diagnostic systems (DSM-5-TR in Schedule 1; ICD-10-AM referenced in s7(3)-(4); other SOPs via s11).","Two parallel series of qualifying factors (s9(1)–(13) for initial causation; s9(14)–(27) for material contribution/worsening) with overlapping items and distinct temporal rules.","Numerous precise timing and dosage thresholds (e.g. 5 years, 12 months, 20 pack-years, 20 years since cessation, 2,000 hours of PM2.5 exposure, inability to undertake >3 METs for 5 years within 20 years).","A non-exhaustive clinical definition requiring application of DSM-5-TR criteria and clinical judgment (s7(2) and Schedule 1 definitions of major/mild neurocognitive disorder).","Defined technical terms in Schedule 1 (albuminuria, MET, chronic kidney disease, specified diseases of cerebral vessels, ambient PM2.5 threshold), increasing interpretive detail.","Conditional application rule in s10(2) that limits some factors to material contribution/aggravation where the disorder was suffered/contracted before or during service but did not arise out of service—adds a layer of conditional logic.","Requirement to reconcile overlapping SOPs where a factor is itself the subject of another SOP (s11), creating potential chaining of instruments.","Practical evidentiary challenges (neuroimaging timing, measuring air pollution exposure, calculating pack-years, functional capacity testing) that complicate routine application."],"plain_english_summary":"**What this instrument does (mechanics)\n\n- Replaces the 2014 Repatriation Medical Authority Statement of Principles on \"vascular dementia\" with a new Statement of Principles (SOP) titled \"vascular neurocognitive disorder\" and brings it into force from 27 March 2023 (see sections 2 and 4). The Authority made the SOP under subsection 196B(3) of the Veterans' Entitlements Act 1986 (s3).\n- It sets the clinical definition of \"vascular neurocognitive disorder\" for the purpose of deciding veteran or member claims under the Veterans' Entitlements Act 1986 (VEA) or the Military Rehabilitation and Compensation Act 2004 (MRCA) (s5, s7(2)). The definition adopts DSM-5-TR diagnostic criteria and lists related conditions included under the term (s7(2) and Schedule 1).\n- It lists the specific factual factors that, if shown on the balance of probabilities, are sufficient to establish that vascular neurocognitive disorder (or death from it) is connected with the person's relevant service (s8–9). The SOP also explains how those factors must be related to the person's relevant service (s10).\n- It cross‑references other SOPs where a listed factor is itself an injury or disease governed by a different SOP (s11).\n\nWho is affected\n\n- Veterans and former or current members of the Australian Defence Force making claims for disability or death benefits under the VEA or MRCA (s5, Schedule 1 definitions of \"relevant service\").\n- Decision-makers in the Department of Veterans' Affairs (or other authorised decision bodies) who must decide entitlement by applying this SOP to medical and service records.\n- Treating clinicians and medical experts who will be asked to provide evidence tying cognitive disorder to the listed factors (for example, imaging, diagnostic test results, smoking history, or records of cardiac events).\n\nWhy it matters (claimed purpose, and practical effect)\n\n- The Repatriation Medical Authority states that, on the medical evidence available, it is \"more probable than not\" that vascular neurocognitive disorder can be related to relevant service (s8). Practically, this SOP provides a list of objective, testable factors that — if present and related to service — allow decision-makers to link the disorder (or death from it) to service on the balance of probabilities (s9).\n\n- Concrete mechanics that change decision outcomes: if a claimant can demonstrate one or more of the listed factors within the timing thresholds in s9 (for example, cerebrovascular accident before onset, hypertension for at least 5 years before onset, certain cardiac conditions, specified imaging findings, defined levels of smoking exposure, specific air pollution exposure, or inability to obtain appropriate clinical management), the SOP creates a presumption-style pathway for establishing a service connection.\n\nAnalytical notes — costs, incentives, trade-offs and implementation issues\n\n- Who pays: successful claims will typically generate liability for government benefits administered by the Department of Veterans' Affairs. The SOP therefore affects public fiscal exposure.\n\n- Who decides and what they must do: decision-makers must apply the SOP to each claim. That requires assembling medical records, neuroimaging, test results, documented service records and exposure histories; and assessing temporal relationships (see s10 on required link to relevant service).\n\n- Compliance burden and evidence costs: the SOP relies on medical tests and quantified exposure histories (neuroimaging, documented cardiac events, pack‑year calculations, METs for physical capacity, 2,000 hours of PM2.5 exposure). Claimants and DVA will likely incur costs in obtaining and reviewing that evidence. Some metrics (for example, calculating 2,000 hours of exposure to PM2.5) may be practically difficult to document.\n\n- Implementation risk and bureaucratic discretion: the SOP sets diagnostic criteria (DSM-5-TR) and bright-line timing thresholds (5 years, 12 months, 20 pack‑years, 2,000 hours, etc.). While this clarifies many cases, the SOP still requires clinical judgment about whether neurocognitive deficits are \"consistent with a vascular aetiology\" (s7(2)B) and whether a listed factor is \"related to\" relevant service (s10). That preserves room for discretionary interpretation in borderline or medically complex cases.\n\n- Incentives and behavioural effects: the SOP creates an incentive for claimants to document and present the specific listed factors and thresholds (for example, prior imaging or a recorded diagnosis of atrial fibrillation). It may also incentivise clinicians to record service-relevant exposures and to provide explicit opinions about vascular aetiology. The SOP may reduce litigation over causation in cases that meet the listed criteria, but increase medical-record disputes in borderline cases.\n\n- Trade-offs and exclusions: the instrument modernises terminology and diagnostic standard (DSM‑5‑TR) and expands covered presentations (including mild neurocognitive disorder and specified vascular pathologies). At the same time, it excludes cases where the cognitive deficits are primarily due to other causes listed in s7(2)E (for example, Alzheimer disease, major depressive disorder as the primary cause, systemic disorders). The SOP therefore shifts the evidentiary battleground to differential diagnosis and timing.\n\n- Effect on private markets and individual choice: the SOP is primarily an administrative/compensation tool. It does not directly regulate private enterprise, markets or competition. Indirectly, by changing claims outcomes, it affects individual claimant incomes and may influence private insurance or care choices, but it does not alter contract freedom or business regulation.\n\nKey operational features to watch (examples with sections)\n\n- Diagnostic standard adopts DSM‑5‑TR definitions for major and mild neurocognitive disorder (s7(2), Schedule 1).\n- Many qualifying factors carry explicit timing or dosage thresholds (e.g., hypertension for at least 5 years before onset — s9(3); cardiac surgery within 12 months before onset — s9(6); smoking ≥20 pack‑years and starting ≥5 years before onset, and cessation within 20 years — s9(8)).\n- Separate lists apply for initial causation (s9(1)–(13)) and for material contribution or aggravation of an existing disorder (s9(14)–(27) and s10(2)).\n- Cross‑application rule: if a listed factor is itself the subject of another SOP, that other SOP governs the factor (s11).\n\nBottom line: the SOP defines a DSM‑5‑TR-based clinical concept of \"vascular neurocognitive disorder,\" supplies a menu of specific, timed medical and exposure factors that can establish a service connection on the balance of probabilities, and replaces the earlier 2014 instrument. It reduces some causal uncertainty by using specified thresholds, but practical decision-making will still require medical judgment about timing, differential diagnosis and whether a qualifying factor is fairly described as ‘‘related to’’ the person's relevant service (see s7, s9–10)."},"kimi_summary":{"content_quality":"ok","complexity_score":6,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It updates the specific condition from 'vascular dementia' to 'vascular neurocognitive disorder' to align with current DSM-5-TR terminology, but does not expand beyond the traditional function of determining service connection for veteran compensation purposes. The shift from 'reasonable hypothesis' to 'balance of probabilities' reflects a standard statutory instrument numbering convention (indicated by the title) rather than a scope expansion."},"complexity_factors":["27 distinct factors with multiple sub-clauses and temporal requirements (e.g., 'at least 5 years before', 'within 12 months before', 'within 20 years of cessation')","14 defined terms in Schedule 1, several with nested definitions (e.g., 'chronic kidney disease' has 4 sub-criteria; 'specified disease of the cerebral vessels' lists 9 specific conditions)","Dual application structure: factors 1-13 for initial onset, factors 14-26 for worsening, with factor 27 (clinical management) applying to both","Cross-references to external medical standards: DSM-5-TR for diagnostic criteria and ICD-10-AM Tenth Edition for coding","Conditional logic in smoking factor: requires pack-year calculation, commencement timing, and cessation window calculations","Section 11 creates dynamic incorporation of other Statements of Principles by reference, meaning the instrument interacts with an unspecified number of other legislative instruments","Specific technical measurements required: METs for physical activity, PM2.5 levels for air pollution, albumin-to-creatinine ratios for kidney disease"],"plain_english_summary":"This instrument replaces the 2014 Statement of Principles with DSM-5-TR–based medical criteria for vascular neurocognitive disorder (vascular dementia), defining what qualifies and what is excluded, and setting 27 medical factors that must be met on the balance of probabilities to link the condition to service. It affects veterans and current/former defence members seeking benefits under veterans’ compensation laws and matters because it raises the evidentiary bar for entitlement."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o","history":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o/history","analysis":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o/analysis","conflicts":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o/important-cases","documents":"/api/acts/statement-of-principles-concerning-vascular-neurocognitive-disorder-balance-of-probabilities-no-10-o/documents"}}